Growth Metrics

NovoCure (NVCR) Cash from Operations (2016 - 2026)

NovoCure's Cash from Operations history spans 13 years, with the latest figure at 13517000.0 for Q1 2026.

  • On a quarterly basis, Cash from Operations rose 62.1% to 13517000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 26883000.0, a 11.74% increase, with the full-year FY2025 number at 49031000.0, down 85.94% from a year prior.
  • Cash from Operations hit 13517000.0 in Q1 2026 for NovoCure, up from 18004000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for NVCR hit a ceiling of 22420000.0 in Q3 2022 and a floor of 35665000.0 in Q1 2025.
  • Historically, Cash from Operations has averaged 7733235.29 across 5 years, with a median of 13517000.0 in 2026.
  • Biggest five-year swings in Cash from Operations: surged 153.72% in 2024 and later tumbled 826.51% in 2025.
  • Tracing NVCR's Cash from Operations over 5 years: stood at 3707000.0 in 2022, then plummeted by 292.72% to 14558000.0 in 2023, then soared by 76.29% to 3451000.0 in 2024, then crashed by 421.7% to 18004000.0 in 2025, then rose by 24.92% to 13517000.0 in 2026.
  • Business Quant data shows Cash from Operations for NVCR at 13517000.0 in Q1 2026, 18004000.0 in Q4 2025, and 20574000.0 in Q3 2025.